Oral anticoagulants: pharmacological aspects and therapeutic therapy
DOI:
https://doi.org/10.33448/rsd-v11i8.30677Keywords:
Deep Vein Thrombosis; Anticoagulants; Pharmacist professional.Abstract
Anticoagulants are highly efficient drugs, however, their use must be analyzed in terms of pharmacological aspects and therapeutic monitoring is crucial and healthy in cases of venous thromboembolism (VTE). Therefore, this study aims to address the pharmacological aspects and how therapeutic monitoring should be carried out in the use of oral anticoagulants in cases of VTE, analyzing studies on the subject. For this, a literature review was carried out, based on studies dated from 2016 to 2022, from scientific databases of studies on the subject, through a narrative literature review. Ten articles were selected. Among the results, it was seen that the ten articles highlighted in the table emphasize types of oral anticoagulants, which varied according to studies, thus achieving the objectives of the study, demonstrating that the new generation of anticoagulants works to direct a specific step of the coagulation cascade and with the possibility of replacing common pharmacological treatments, bringing greater safety and reduction of side effects. Concluding that anticoagulant therapy was based almost exclusively on the use of heparin, but that over the last few decades, more studies have been developed and new classes of anticoagulant drugs have significantly changed the therapeutic arsenal, bringing greater efficacy and safety in relation to conventional treatment within of the clinical context.
References
Andrade, V. (2016). Os Novos Anticoagulantes Orais no Tratamento do Tromboembolismo Pulmonar. Trabalho Final do Mestrado Integrado em Medicina, Faculdade de Lisboa, 36f.
Brandão, G. M. S. et al (2018) Anticoagulantes orais diretos para o tratamento da trombose venosa profunda: revisão de revisões sistemáticas. Vascular Brasileiro [online]. 17(4): 310-317.
Connolly, S. J., Milling, T.. J. Jr., Eikelboom, J.W., Gibson, C. M., Curnutte, J. T. & Gold, A., et al; (2016). ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med,;375(12):1131-41.
Elias, C. S. R., Silva, L. A., Martins, M. T., Ramos, N. A. P. R., Souza, M. G. G. & Hipólito, R. L. (2012) chega ao fim? Uma revisão narrativa sobre terminalidade do período escolar para alunos deficientes mentais. SMAD: Revista Electrónica em Salud Mental, Alcohol y Drogas, 8(1): 48-53.
Fernandes, C. J., Leonidas, J. L., Gavilanes, F., Prada, L. F., Morinaga, L., & Souza, R. (2016). Os novos anticoagulantes no tratamento do tromboembolismo venoso. J Bras Pneumo, 42(2):146-154.
Figueiredo, T. R., Braz Costa, C., Melo, M., De Araújo, H. V., Silva, T., & Silva Bezerra, M. (2018). Adesão farmacológica e conhecimento de pacientes anticoagulados, Av Enferm, 36(2): 143-152.
Gil, A. C. (2011). Como elaborar projetos de pesquisa. (4a ed.), Atlas.
Gomes, P. L., Silva, A. A., & Rodrigues Junior, O. M. (2021). Uso de anticoagulantes en pacientes hospitalizados por trombosis venosa profunda en membros Inferiores. Research, Society and Development, 10(15), e46101522699.
Habib, A., Petrucci, G., & Rocca, B. (2020). Pathophysiology of Thrombosis in Peripheral Artery Disease. Curr Vasc Pharmacol, 18(3): 204-214.
Hu, X., Xiao, Y., Yu, C., Yinglin, Z., Yang, W., Wang, X., Baohua, G & Jing, L. (2018). Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding. Eur J Pharmacol, 15(8): 85-91.
Kearon, C., Akl, E. A., Ornelas, J. et al. (2016). Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. CHEST; 149(2): 315-352.
Moheimani, F., Jackson, D. (2016) Venous Thromboembolism: Classification, Risk Factors, Diagnosis, and Management. SRN Hematol, 12(5).
Nieto, J.A., Solano, R., Ruiz-Ribó, M. D. Ruiz-Gimenez, N., Prandoni, P. &Kearon C, et al. (2016). Fatal bleeding in patients receiving anticoagulante therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost; 8(6):1216-22.
Praxedes, M. F. et al. (2017) Adaptação Transcultural do Oral Anticoagulation Knowledge Test para o Português do Brasil. Ciência & Saúde Coletiva [online]. 22(5): 1615-1629.
Qiu, X., Zhou, J., Wang, W., Zhao, Z., Tang, L., & Sun, J. (2019). Effect of a new inhibitor of factor Xa zifaxaban, on thrombosis in the inferior vena cava in rabbits. J Thromb Thrombolysis; 47(1): 80-86.
Sampaio, G. M., Cândido, R. C., Rollo, H. A., & Sobreira, D. J. (2018). Anticoagulantes orais diretos para o tratamento da trombose venosa profunda: revisão de revisões sistemáticas, J. Vasc. Bras, 17(4).
Serra, I. C., et al. (2016) Gestão terapêutica dos utentes com terapia anticoagulante oral. Enferm. glob., Murcia, 15 (41): 10-19.
Serrano Jr, C.V., Soeiro, A.M., Leal, T.C.A.T., Godoy, L.C., Biselli, B., Hata, L. A. et al. (2019). Posicionamento sobre Antiagregantes Plaquetários e Anticoagulantes em Cardiologia, Arq Bras Cardiol 113(1):111-134.
Schulman, S., Kakkar, A.K., Goldhaber, S.Z., Schellong, S., Eriksson, H., Mismetti, P., et al. (2016). Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation, 129(7):764-72.
Silva, R. D. R., & Melo, E. M. (2016). A atual teoria da coagulação baseada em superfícies celulares. Saúde & Ciência em Ação. Revista Acadêmica do Instituto de Ciências da Saúde, 2(1): 79-92.
Stefano, V., Finazzi, G., & Barbui, T. (2018) Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. Blood Cancer J, 8(7): 65.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 André Pires de Oliveira Silva; João Paulo Costa Lima; Sérgio Ruas Nascimento; Aline Teixeira Amorim
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
